Stock Events

Stock Events

Neumora Therapeutics 

$0.4549
72
+$0.09+23.88% 18:43 Today

Statistics

Day High
0.4599
Day Low
0.3648
52W High
3.65
52W Low
0.315
Volume
1,866,542
Avg. Volume
1,449,926
Mkt Cap
85.47M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 4Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.42
-0.35
-0.27
-0.2
Expected EPS
-0.196563
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
2025
0Revenue
-236.93MNet Income

Analyst Ratings

$5.25Average Price Target
The highest estimate is ⁦7.00⁩.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NMRA. It's not an investment recommendation.
NVIDIA
15
NVDA
Amazon
14
AMZN
Apple
13
AAPL
SoFi Technologies
13
SOFI

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Axsome Therapeutics
AXSM
Mkt Cap7.57B
Axsome Therapeutics develops novel therapies for central nervous system (CNS) conditions, including major depressive disorder, directly overlapping with Neumora's therapeutic areas.
BridgeBio Pharma
BBIO
Mkt Cap14.6B
BridgeBio Pharma targets genetic diseases and genetically defined cancers, including CNS disorders, making it a competitor in the neuropsychiatric space.
Alkermes
ALKS
Mkt Cap7.61B
Alkermes plc has a portfolio including treatments for schizophrenia and bipolar I disorder, areas that Neumora may also target.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurodegenerative diseases, including Alzheimer's, which may overlap with Neumora's interest in neuropsychiatric and neurodegenerative disorders.
AMGEN
AMGN
Mkt Cap251.94B
Amgen's broad focus on innovative therapeutics includes CNS disorders, positioning it as a competitor in the neuropsychiatric field.
Novartis
NVS
Mkt Cap303.67B
Novartis has a diverse portfolio that includes neuroscience, making it a competitor in developing treatments for CNS disorders.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a long history in CNS disorders, including developing treatments for neurological and psychiatric conditions, making it a competitor.

About

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Show More
CEO
Josh Pinto
Employees
63
Country
United States
ISIN
US6409791000

Listings

XNAS
US
NMRA
BOATS
BOATS
NMRA.BOATS

0 Comments

Share your thoughts

FAQs

What is Neumora Therapeutics stock price today?▼
The current price of NMRA is $0.45 USD — it has increased by +23.88% in the past 24 hours. Watch Neumora Therapeutics stock price performance more closely on the chart.
What is Neumora Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Neumora Therapeutics stocks are traded under the ticker NMRA.
Is Neumora Therapeutics stock price growing?▼
NMRA stock has risen by +14.51% compared to the previous week, the month change is a -10% fall, over the last year Neumora Therapeutics has showed a -85.1% decrease.
What is Neumora Therapeutics market cap?▼
Today Neumora Therapeutics has the market capitalization of 85.47M
When is the next Neumora Therapeutics earnings date?▼
Neumora Therapeutics is going to release the next earnings report on November 4, 2026.
What were Neumora Therapeutics earnings last quarter?▼
NMRA earnings for the last quarter are -0.23 USD per share, whereas the estimation was -0.24 USD resulting in a +4.2% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Neumora Therapeutics revenue for the last year?▼
Neumora Therapeutics revenue for the last year amounts to 0 USD.
What is Neumora Therapeutics net income for the last year?▼
NMRA net income for the last year is -236.93M USD.
How many employees does Neumora Therapeutics have?▼
As of November 2, 2026, the company has 63 employees.
In which sector is Neumora Therapeutics located?▼
Neumora Therapeutics operates in the Health & Wellness sector.
When did Neumora Therapeutics complete a stock split?▼
Neumora Therapeutics has not had any recent stock splits.
Where is Neumora Therapeutics headquartered?▼
Neumora Therapeutics is headquartered in WATERTOWN, United States.